Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCariporide is a selective Na+/H+ exchanger isoform 1 (NHE1) inhibitor (IC50 values are 0.05, 3 and 1000 μM for NHE1, NHE3 and NHE2 respectively). Attenuates ischemia-induced cardiomyocyte apoptosis in vitro. Reduces cardiac arrhythmia in vivo. Also promotes apoptosis in cancer cells overexpressing NHE1. Orally active.
Cariporide is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 283.35 |
Formula | C12H17N3O3S |
Storage | Store at +4°C |
Purity | ≥98% (HPLC) |
CAS Number | 159138-80-4 |
PubChem ID | 151172 |
InChI Key | IWXNYAIICFKCTM-UHFFFAOYSA-N |
Smiles | CC(C)C1=C(S(C)(=O)=O)C=C(C(NC(N)=N)=O)C=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 28.34 | 100 |
The following data is based on the product molecular weight 283.35. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 3.53 mL | 17.65 mL | 35.29 mL |
5 mM | 0.71 mL | 3.53 mL | 7.06 mL |
10 mM | 0.35 mL | 1.76 mL | 3.53 mL |
50 mM | 0.07 mL | 0.35 mL | 0.71 mL |
References are publications that support the biological activity of the product.
Scholz et al (1995) Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion. Cardiovasc.Res. 29 260 PMID: 7736504
Chakrabarti et al (1997) A rapid ischemia-induced apoptosis in isolated rat hearts and its attenuation by the sodium-hydrogen exchange inhibitor HOE 642 (cariporide). J.Mol.Cell.Cardiol. 29 3169 PMID: 9405190
Teshima et al (2003) Cariporide (HOE642), a selective Na+-H+ exchange inhibitor, inhibits the mitochondrial death pathway. Circulation 108 2275 PMID: 14568900
Harguindey et al (2013) Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs--an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research. J.Transl.Med. 11 282 PMID: 24195657
If you know of a relevant reference for Cariporide, please let us know.
Keywords: Cariporide, Cariporide supplier, Cariporide, HOE642, selective, sodium, hydrogen, exchanger, NHE1, inhibitors, inhibits, cardioprotective, cardiomyocytes, ischemia, orally, active, Na+/H+, HOE, 642, Exchanger, 5358, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for Cariporide include:
Alzbeta et al (2022) Solute exchange through gap junctions lessens the adverse effects of inactivating mutations in metabolite-handling genes. Elife 11 PMID: 36107487
Do you know of a great paper that uses Cariporide from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Cariporide and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.